Single nucleotide polymorphisms in the IGF‐IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE‐3 trial
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30715
Abstract: The Insulin‐like growth factor (IGF)/IGF‐receptor pathway with its scaffolding proteins Insulin Receptor Substrate (IRS)1 and IRS2 are crucial regulators of metabolism and progression in metastatic colorectal cancer (mCRC). The goal of the study was the… read more here.
Keywords: patients enrolled; fire trial; mcrc; igf ... See more keywords
Maintenance Versus Intermittent Strategies in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis from Another Angle
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01059-5
Abstract: Considering the differences in overall survival (OS) and progression-free survival (PFS), treatment options for metastatic colorectal cancer (mCRC) are still inconclusive. We carried out a meta-analysis of maintenance and intermittent strategies for the treatment of… read more here.
Keywords: intermittent; mcrc; maintenance; treatment ... See more keywords
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical colorectal cancer"
DOI: 10.1016/j.clcc.2019.04.003
Abstract: BACKGROUND Current guidelines of the National Comprehensive Cancer Network and the European Society of Medical Oncology recommend regorafenib or trifluridine/tipiracil (TAS-102) for third-line therapy of metastatic colorectal cancer (mCRC). We evaluated the impact of regorafenib… read more here.
Keywords: muscle; tas 102; cancer; skeletal muscle ... See more keywords
Strategies to tackle RAS-mutated metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100156
Abstract: The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal… read more here.
Keywords: metastatic colorectal; mcrc; ras targeting; colorectal cancer ... See more keywords
Agreement between hospital discharge diagnosis codes and medical records to identify metastatic colorectal cancer and associated comorbidities in elderly patients.
Sign Up to like & getrecommendations! Published in 2017 at "Revue d'epidemiologie et de sante publique"
DOI: 10.1016/j.respe.2017.03.132
Abstract: BACKGROUND Quality of coding to identify cancers and comorbidities through the French hospital diagnosis database (Programme de médicalisation des systèmes d'information, PMSI) has been little investigated. Agreement between medical records and PMSI database was evaluated… read more here.
Keywords: agreement; mcrc; diagnosis codes; diagnosis ... See more keywords
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01076-0
Abstract: Background Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a… read more here.
Keywords: metastatic colorectal; mcrc; immunotherapy; colorectal cancer ... See more keywords
Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1470729
Abstract: ABSTRACT The tumor microenvironment (TME) represents a significant barrier to creating effective therapies for metastatic colorectal cancer (mCRC). In several malignancies, bone marrow derived CCR2+ inflammatory monocytes (IM) are recruited to the TME by neoplastic… read more here.
Keywords: mcrc; tumor associated; ccr2; colorectal cancer ... See more keywords
Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz365
Abstract: Abstract Several cancer genome alterations have been identified as important targets for mCRC treatment, which include BRAF mutation, HER-2 amplification/expression, microsatellite instability-high (MSI-H) and etc., for which corresponding agents showed promising activity in clinical trials.… read more here.
Keywords: cancer genome; mcrc; clinical development; treatment ... See more keywords
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005332
Abstract: Background Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study investigates whether the combination of trametinib (T) with durvalumab (D) can alter the immune… read more here.
Keywords: cancer; microsatellite stable; mcrc; response ... See more keywords
Abstract 5296: Instability of non standard microsatellites in metastatic colorectal cancer patients treated with a bevacizumab based chemotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-5296
Abstract: Bevacizumab (B) is a biological agent frequently included in the treatment of metastatic colon cancer (mCRC), although at present there is no effective biomarker that can predict its efficacy. Few studies report a positive association… read more here.
Keywords: chemotherapy; mcrc; msi; patients treated ... See more keywords
Abstract 4406: Impact of site of metastases on response to immunotherapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4406
Abstract: Background: We have noted that responses to the combinations of regorafenib and nivolumab (REGONIVO) or regorafenib ipilimumab nivolumab (RIN) were limited to MSS mCRC without liver involvement. We sought to delineate the impact of non-liver… read more here.
Keywords: disease; impact; mcrc; metastatic disease ... See more keywords